Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV

被引:32
作者
Baxi, Sanjiv M. [1 ,2 ]
Scherzer, Rebecca [1 ,3 ]
Greenblatt, Ruth M. [4 ,5 ]
Minkoff, Howard [6 ]
Sharma, Anjali [7 ]
Cohen, Mardge [8 ]
Young, Mary A. [9 ]
Abraham, Alison G. [10 ]
Shlipak, Michael G. [1 ,3 ,5 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
[3] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[6] Suny Downstate Med Ctr, Div Infect Dis, Brooklyn, NY 11203 USA
[7] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[8] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Div Infect Dis, Chicago, IL USA
[9] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA
[10] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
adverse drug effect; HIV; kidney function; pharmacokinetics; tenofovir; Women's Interagency HIV Study; DISOPROXIL FUMARATE; INFECTED PATIENTS; RENAL TOXICITY; INCOMPLETE REVERSIBILITY; ANTIRETROVIRAL ACTIVITY; PLASMA-CONCENTRATIONS; CLINICAL-TRIALS; PHASE I/II; PHARMACOKINETICS; ALAFENAMIDE;
D O I
10.1097/QAD.0000000000000958
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective:Tenofovir disoproxil fumarate is a commonly used antiretroviral drug, but risk factors for tenofovir (TFV)-associated kidney disease are not fully understood. We used intensive pharmacokinetic studies in a cohort of HIV-infected women on TFV-based therapy to study the relationship between TFV exposure and subsequent kidney function.Design:This is a nested study within the Women's Interagency HIV Study, a multicenter, prospective cohort of HIV-infected women. Participants on TFV-based therapy underwent 24-h intensive pharmacokinetic sampling after witnessed dose. Kidney function was measured over the succeeding 7 years by serum creatinine [estimated glomerular filtration rate calculated by serum creatinine (eGFRcr)].Methods:Multivariable linear mixed models evaluated the relationship of baseline TFV area under the-time concentration curves (AUCs) with subsequent changes in kidney function. Covariates included age, diabetes, hypertension, race, BMI, ritonavir use, duration of TFV exposure, current CD4(+) cell count, and HIV viral load.Results:Of the 105 participants, persons within the highest baseline TFV AUC tertile had significantly lower eGFRcr compared with those in the lowest tertile (meanstandard error: 80 +/- 4.3 vs. 104 +/- 2.5ml/min per 1.73m(2), P<0.0001). By year 7, this difference widened (72 +/- 4.9 vs. 105 +/- 2.9, P<0.0001). After multivariable adjustment, TFV AUC in the highest tertile remained associated with lower eGFRcr relative to values in the lowest tertile at both baseline (-15ml/min per 1.73m(2), P=0.0047) and year 7 (-23ml/min per 1.73m(2), P=0.0002).Conclusion:Through intensive TFV pharmacokinetic sampling, we found a strong association between greater TFV exposure and subsequent decline in kidney function. Variations in TFV drug exposure may partially account for subsequent nephrotoxicity in persons infected with HIV. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:609 / 617
页数:9
相关论文
共 43 条
[1]   Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney [J].
Abraham, Premila ;
Ramamoorthy, Hemalatha ;
Isaac, Bina .
JOURNAL OF BIOMEDICAL SCIENCE, 2013, 20
[2]   Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients [J].
Baheti, Gautam ;
Kiser, Jennifer J. ;
Havens, Peter L. ;
Fletcher, Courtney V. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) :5294-5299
[3]   Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity [J].
Bam, Rujuta A. ;
Yant, Stephen R. ;
Cihlar, Tomas .
ANTIVIRAL THERAPY, 2014, 19 (07) :687-692
[4]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[5]   The Women's Interagency HIV Study [J].
Barkan, SE ;
Melnick, SL ;
Preston-Martin, S ;
Weber, K ;
Kalish, LA ;
Miotti, P ;
Young, M ;
Greenblatt, R ;
Sacks, H ;
Feldman, J .
EPIDEMIOLOGY, 1998, 9 (02) :117-125
[6]   Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women [J].
Baxi, Sanjiv M. ;
Greenblatt, Ruth M. ;
Bacchetti, Peter ;
Scherzer, Rebecca ;
Minkoff, Howard ;
Huang, Yong ;
Anastos, Kathryn ;
Cohen, Mardge ;
Gange, Stephen J. ;
Young, Mary ;
Shlipak, Michael G. ;
Gandhi, Monica .
AIDS, 2014, 28 (01) :59-66
[7]   Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients [J].
Calza, Leonardo ;
Trapani, Filippo ;
Tedeschi, Sara ;
Piergentili, Benedetta ;
Manfredi, Roberto ;
Colangeli, Vincenzo ;
Viale, Pierluigi .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (08) :656-660
[8]   The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards [J].
Delahunty, Tom ;
Bushman, Lane ;
Robbins, Brian ;
Fletcher, Courtney V. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (20-21) :1907-1914
[9]   Recruitment and Retention of Diverse Populations in Antiretroviral Clinical Trials: Practical Applications from the Gender, Race And Clinical Experience Study [J].
Falcon, Ron ;
Bridge, Dawn Averitt ;
Currier, Judith ;
Squires, Kathleen ;
Hagins, Debbie ;
Schaible, Deborah ;
Ryan, Robert ;
Mrus, Joseph .
JOURNAL OF WOMENS HEALTH, 2011, 20 (07) :1043-1050
[10]   Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort [J].
Gagneux-Brunon, Amandine ;
Delanaye, Pierre ;
Maillard, Nicolas ;
Fresard, Anne ;
Basset, Thierry ;
Alamartine, Eric ;
Lucht, Frederic ;
Pottel, Hans ;
Mariat, Christophe .
AIDS, 2013, 27 (10) :1573-1581